Mr. Hermes Chan reports

MEDMIRA TARGETS TECHNOLOGY PROMOTION WITH LATEST INVESTMENT FROM ONSITE LAB

Medmira Inc. is entering into a $5-million investment with OnSite Lab Holding AG to increase promotion and brand building to position the company's proprietary Rapid Vertical Flow (RVF) Technology as a dominant platform in the rapid diagnostics industry.

"Medmira has always been about technology; our initial focus began with the development of RVF Technology and we expanded into product applications as a way to validate the technology. In many ways, we've come full circle -- as more people use our product applications, we continue to evolve the capabilities of RVF Technology and the value it delivers," said Hermes Chan, co-founder and chief executive officer of Medmira. "With the launch of Miriad and promoting RVF as a development platform, we realized that there are untapped opportunities, collaborations and partnerships where our technology can play an important role. OnSite Lab's new investment will help us quickly and strategically capitalize on the potential of RVF Technology to become a leading provider of diagnostic technology."

As the company positions itself for a strategic focus on technology, it is adding scientific and industry expert resources to support these advancements. Last month, Dr. Philippe Dro joined Medmira's board of directors, bringing with him a strong business network in the biotech sector, which will be valuable as the company increases its business development initiatives focused on RVF technology. Joining Medmira as an independent scientific adviser is Dr. Christian Surber, a professor of dermatopharmacology and hospital pharmacy at the University of Basel. A leader in his field, Dr. Surber's deep scientific expertise will complement Medmira's research and development (R&D) team as it continues to advance the RVF Technology platform.

Mr. Chan continued, "We are pleased to have both Dr. Dro and Dr. Surber join Medmira and look forward to their guidance and insight as we optimize the scientific advancement and promotion of our RVF Technology platform to sharpen Medmira's market position."

Medmira pioneered the development and advancement of RVF Technology and it remains the company's core focus. While many clinical applications have already been developed using RVF Technology, including Medmira's own line of rapid tests for HIV, hepatitis B and C, and syphilis, the company has set its sights on marketing RVF Technology as a platform for other diagnostic developers and researchers to build on with a path to future commercialization. These opportunities range from R&D collaboration to custom development and contract manufacturing opportunities for new applications in sectors including human health, vaccine development, veterinary, environmental and others.

Under the terms of deal, OnSite Lab will acquire 100 million equity units at five cents per unit. Each equity unit consists of one common share and one common share purchase warrant and is subject to a four-month hold period that expires on Jan. 5, 2016. Each full warrant entitles the investor to purchase one common share of Medmira at 10 cents per share, exercisable over four years. OnSite Lab is the company's controlling shareholder and has previously made investments in Medmira totalling $18.7-million.

We seek Safe Harbor.